1 |
2D 1H-1H TOCSY |
0.58 mM Heterogeneous-backbone analogue of plectasin variant NZ2114: alpha-Me-Leu13, Aib17, alpha-Me-Lys20, 20 mM [U-2H] sodium acetate, 0.13 mM 4,4-dimethyl-4-silapentane-1-ammonium trifluoroacetate (DSA), 90% H2O/10% D2O |
29 |
90% H2O/10% D2O |
3.8 |
1 |
298 |
2 |
2D 1H-1H COSY |
0.58 mM Heterogeneous-backbone analogue of plectasin variant NZ2114: alpha-Me-Leu13, Aib17, alpha-Me-Lys20, 20 mM [U-2H] sodium acetate, 0.13 mM 4,4-dimethyl-4-silapentane-1-ammonium trifluoroacetate (DSA), 90% H2O/10% D2O |
29 |
90% H2O/10% D2O |
3.8 |
1 |
298 |
3 |
2D DQF-COSY |
0.58 mM Heterogeneous-backbone analogue of plectasin variant NZ2114: alpha-Me-Leu13, Aib17, alpha-Me-Lys20, 20 mM [U-2H] sodium acetate, 0.13 mM 4,4-dimethyl-4-silapentane-1-ammonium trifluoroacetate (DSA), 90% H2O/10% D2O |
29 |
90% H2O/10% D2O |
3.8 |
1 |
298 |
4 |
2D 1H-1H NOESY |
0.58 mM Heterogeneous-backbone analogue of plectasin variant NZ2114: alpha-Me-Leu13, Aib17, alpha-Me-Lys20, 20 mM [U-2H] sodium acetate, 0.13 mM 4,4-dimethyl-4-silapentane-1-ammonium trifluoroacetate (DSA), 90% H2O/10% D2O |
29 |
90% H2O/10% D2O |
3.8 |
1 |
298 |